GB9712866D0 - Novel method of treatment - Google Patents

Novel method of treatment

Info

Publication number
GB9712866D0
GB9712866D0 GBGB9712866.4A GB9712866A GB9712866D0 GB 9712866 D0 GB9712866 D0 GB 9712866D0 GB 9712866 A GB9712866 A GB 9712866A GB 9712866 D0 GB9712866 D0 GB 9712866D0
Authority
GB
United Kingdom
Prior art keywords
treatment
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9712866.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9712866.4A priority Critical patent/GB9712866D0/en
Publication of GB9712866D0 publication Critical patent/GB9712866D0/en
Priority to CNB988062232A priority patent/CN1133431C/zh
Priority to BR9810444-6A priority patent/BR9810444A/pt
Priority to SK1793-99A priority patent/SK179399A3/sk
Priority to IDW991627A priority patent/ID23951A/id
Priority to EA200000042A priority patent/EA004800B1/ru
Priority to PL98343123A priority patent/PL343123A1/xx
Priority to IL13314398A priority patent/IL133143A0/xx
Priority to AU82163/98A priority patent/AU8216398A/en
Priority to APAP/P/1999/001718A priority patent/AP1287A/en
Priority to PCT/EP1998/003692 priority patent/WO1998057636A1/en
Priority to KR1019997011864A priority patent/KR20010013843A/ko
Priority to TR1999/03095T priority patent/TR199903095T2/xx
Priority to CA002294141A priority patent/CA2294141A1/en
Priority to NZ518076A priority patent/NZ518076A/en
Priority to EP98932169A priority patent/EP0999837A1/en
Priority to JP50375799A priority patent/JP2002504138A/ja
Priority to HU0003260A priority patent/HUP0003260A3/hu
Priority to UA99126881A priority patent/UA70299C2/uk
Priority to MA25122A priority patent/MA26511A1/fr
Priority to DZ980131A priority patent/DZ2521A1/xx
Priority to ARP980102886A priority patent/AR015894A1/es
Priority to ARP980102883A priority patent/AR012997A1/es
Priority to ZA9805237A priority patent/ZA985237B/xx
Priority to TW087109619A priority patent/TW587937B/zh
Priority to UY25050A priority patent/UY25050A1/es
Priority to PE1998000535A priority patent/PE104499A1/es
Priority to IN1698DE1998 priority patent/IN189723B/en
Priority to CO98034654A priority patent/CO4940454A1/es
Priority to NO996265A priority patent/NO996265L/no
Priority to OA9900296A priority patent/OA11517A/en
Priority to BG104059A priority patent/BG104059A/xx
Priority to US09/928,326 priority patent/US20020028768A1/en
Priority to US10/722,205 priority patent/US20040106543A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GBGB9712866.4A 1997-06-18 1997-06-18 Novel method of treatment Pending GB9712866D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
AU82163/98A AU8216398A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
JP50375799A JP2002504138A (ja) 1997-06-18 1998-06-15 ロシグリタゾンおよびインスリンを用いる糖尿病の治療
BR9810444-6A BR9810444A (pt) 1997-06-18 1998-06-15 Tratamento de diabete com rosiglitazona e insulina
SK1793-99A SK179399A3 (en) 1997-06-18 1998-06-15 Use of insulin sensitiser and an insulin
IDW991627A ID23951A (id) 1997-06-18 1998-06-15 Pengobatan diabetes dengan rosiglitazon dan insulin
HU0003260A HUP0003260A3 (en) 1997-06-18 1998-06-15 Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
PL98343123A PL343123A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
IL13314398A IL133143A0 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
UA99126881A UA70299C2 (en) 1997-06-18 1998-06-15 Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin
APAP/P/1999/001718A AP1287A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin.
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
KR1019997011864A KR20010013843A (ko) 1997-06-18 1998-06-15 로지글리타존 및 인슐린을 사용한 당뇨병의 치료
TR1999/03095T TR199903095T2 (xx) 1997-06-18 1998-06-15 Diabetin roziglitazon ve ins�lin ile tedavisi.
CA002294141A CA2294141A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
NZ518076A NZ518076A (en) 1997-06-18 1998-06-15 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
EP98932169A EP0999837A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
CNB988062232A CN1133431C (zh) 1997-06-18 1998-06-15 用罗西格列酮和胰岛素治疗糖尿病
EA200000042A EA004800B1 (ru) 1997-06-18 1998-06-15 Способ лечения диабета росиглитазоном и инсулином
TW087109619A TW587937B (en) 1997-06-18 1998-06-17 Pharmaceutical composition for treating diabetes mellitus and conditions associated with diabetes mellitus
MA25122A MA26511A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l'insuline pour une methode de traitement.
DZ980131A DZ2521A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.
ARP980102886A AR015894A1 (es) 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
ARP980102883A AR012997A1 (es) 1997-06-18 1998-06-17 Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
ZA9805237A ZA985237B (en) 1997-06-18 1998-06-17 Novel method of treatment.
CO98034654A CO4940454A1 (es) 1997-06-18 1998-06-18 Nuevo metodo de tratamiento
PE1998000535A PE104499A1 (es) 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
UY25050A UY25050A1 (es) 1997-06-18 1998-06-18 Metodo de tratamiento para diabetes mellitus
IN1698DE1998 IN189723B (xx) 1997-06-18 1998-06-18
NO996265A NO996265L (no) 1997-06-18 1999-12-17 Behandling av diabetes med rosiglitazon og insulin
OA9900296A OA11517A (en) 1997-06-18 1999-12-17 Treatment of diabetes with rosiglitazone and insulin.
BG104059A BG104059A (en) 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin
US09/928,326 US20020028768A1 (en) 1997-06-18 2001-08-13 Treatment of diabetes with rosiglitazone and insulin
US10/722,205 US20040106543A1 (en) 1997-06-18 2003-11-25 Treatment of diabetes with rosiglitazone and insulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
GB9712866D0 true GB9712866D0 (en) 1997-08-20

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9712866.4A Pending GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Country Status (30)

Country Link
EP (1) EP0999837A1 (xx)
JP (1) JP2002504138A (xx)
KR (1) KR20010013843A (xx)
CN (1) CN1133431C (xx)
AP (1) AP1287A (xx)
AR (2) AR015894A1 (xx)
AU (1) AU8216398A (xx)
BG (1) BG104059A (xx)
BR (1) BR9810444A (xx)
CA (1) CA2294141A1 (xx)
CO (1) CO4940454A1 (xx)
DZ (1) DZ2521A1 (xx)
EA (1) EA004800B1 (xx)
GB (1) GB9712866D0 (xx)
HU (1) HUP0003260A3 (xx)
ID (1) ID23951A (xx)
IL (1) IL133143A0 (xx)
IN (1) IN189723B (xx)
MA (1) MA26511A1 (xx)
NO (1) NO996265L (xx)
OA (1) OA11517A (xx)
PE (1) PE104499A1 (xx)
PL (1) PL343123A1 (xx)
SK (1) SK179399A3 (xx)
TR (1) TR199903095T2 (xx)
TW (1) TW587937B (xx)
UA (1) UA70299C2 (xx)
UY (1) UY25050A1 (xx)
WO (1) WO1998057636A1 (xx)
ZA (1) ZA985237B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
BR0316091A (pt) * 2002-11-08 2005-09-27 Hoffmann La Roche Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228260B1 (en) * 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister

Also Published As

Publication number Publication date
AP9901718A0 (en) 1999-12-31
PE104499A1 (es) 2000-01-13
CN1260715A (zh) 2000-07-19
IN189723B (xx) 2003-04-19
AR015894A1 (es) 2001-05-30
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
OA11517A (en) 2004-02-04
IL133143A0 (en) 2001-03-19
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
UA70299C2 (en) 2004-10-15
EA200000042A1 (ru) 2000-08-28
SK179399A3 (en) 2000-11-07
HUP0003260A2 (hu) 2001-05-28
AU8216398A (en) 1999-01-04
ID23951A (id) 2000-06-08
EA004800B1 (ru) 2004-08-26
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
BR9810444A (pt) 2000-09-05
DZ2521A1 (fr) 2003-02-08
TW587937B (en) 2004-05-21
BG104059A (en) 2000-10-31
ZA985237B (en) 2000-02-17
CA2294141A1 (en) 1998-12-23
UY25050A1 (es) 2000-09-29
AP1287A (en) 2004-06-26
NO996265D0 (no) 1999-12-17
HUP0003260A3 (en) 2001-12-28
WO1998057636A1 (en) 1998-12-23
NO996265L (no) 1999-12-17
PL343123A1 (en) 2001-07-30
TR199903095T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
ZA977564B (en) Method of treatment
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
GB9715298D0 (en) Novel method of treatment
GB9715306D0 (en) Novel method of treatment
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
IL139943A0 (en) Method of treatment
GB9824893D0 (en) Novel method of treatment
GB9415902D0 (en) Method of treatment
EG24157A (en) Novel method of treatment
EG24199A (en) Novel method of treatment
GB9407335D0 (en) Method of treatment
GB9712865D0 (en) Novel method of treatment
GB9724289D0 (en) Method of treatment
GB9717399D0 (en) Method of treatment
EG24158A (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
GB9414652D0 (en) Method of treatment
GB9701448D0 (en) Methods of treatment
GB9824871D0 (en) Novel method of treatment
GB9824789D0 (en) Novel method of treatment
GB9824790D0 (en) Novel method of treatment
SI1135128T1 (sl) Nov postopek zdravljenja